5. Conclusion

In this study, we focused on the fast delivery of the PS by HVJ-E and have demonstrated highly selective cytotoxicity of in vitro PDT using PE against drug-resistant prostate cancer cells with a short drug-light interval. This result suggests that PE-mediated PDT can shorten drug-light interval and reduce PDT-mediated side effects, and gives the possibility to apply PDT to a novel treatment modality for drug-resistant prostate cancer in clinical.


We are deeply grateful to Erica Miyake Lin for technical assistance with the experiments. This work was supported by JSPS KAKENHI Grant Number JP15K16322 and JGC-S SCHOLARSHIP FOUNDATION Grant Number 1605.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Quon, H., Loblaw, A. and Nam, R. (2011) Dramatic Increase in Prostate Cancer Cases by 2021. BJU International, 108, 1734-1738.
[2] Fuessel, S., Meye, A., Schmitz, M., Zastrow, S., Linné, C., Richter, K., Löbel, B., Hakenberg, O.W., Hoelig, K., Rieber, E.P. and Wirth, M.P. (2006) Vaccination of Hormone-Refractory Prostate Cancer Patients with Peptide Cocktail-Loaded Dendritic Cells: Results of a Phase I Clinical Trial. The Prostate, 66, 811-821.
[3] Bhandari, M.S., Petrylak, D.P. and Hussain, M. (2005) Clinical Trials in Metastatic Prostate Cancer—Has There Been Real Progress in the Past Decade? European Journal of Cancer, 41, 941-953.
[4] Baier, J., Maier, M., Engl, R., Landthaler, M. and Bäumler, W. (2005) Time-Resolved Investigations of Singlet Oxygen Luminescence in Water, in Phosphatidylcholine, and in Aqueous Suspensions of Phosphatidylcholine or HT29 Cells. The Journal of Physical Chemistry B, 109, 3041-3046.
[5] Ethirajan, M., Chen, Y., Joshi, P. and Pandey, R.K. (2011) The Role of Porphyrin Chemistry in Tumor Imaging and Photodynamic Therapy. Chemical Society Reviews, 40, 340-362.
[6] Usuda, J., Kato, H., Okunaka, T., Furukawa, K., Tsutsui, H., Yamada, K., Suga, Y., Honda, H., Nagatsuka, Y., Ohira, T., Tsuboi, M. and Hirano, T. (2006) Photodynamic Therapy (PDT) for Lung Cancers. Journal of Thoracic Oncology, 1, 489-493.
[7] Trachtenberg, J., Bogaards, A., Weersink, R.A., Haider, M.A., Evans, A., McCluskey, S.A., Scherz, A., Gertner, M.R., Yue, C., Appu, S., Aprikian, A., Savard, J., Wilson, B.C. and Elhilali, M. (2007) Vascular Targeted Photodynamic Therapy with Palladium-Bacteriopheophorbide Photosensitizer for Recurrent Prostate Cancer Following Definitive Radiation Therapy: Assessment of Safety and Treatment Response. The Journal of Urology, 178, 1974-1979.
[8] Trachtenberg, J., Weersink, R.A., Davidson, S.R.H., Haider, M.A., Bogaards, A., Gertner, M.R., Evans, A., Scherz, A., Savard, J., Chin, J.L., Wilson, B.C. and Elhilali, M. (2008) Vascular-Targeted Photodynamic Therapy (Padoporfin, WST09) for Recurrent Prostate Cancer after Failure of External Beam Radiotherapy: A Study of Escalating Light Doses. BJU International, 102, 556-562.
[9] Xua, D.D., Lamb, H.M., Hoevenc, R., Xu, C.B., Leung, A.W.N. and Cho, W.C.S. (2013) Photodynamic Therapy Induced Cell Death of Hormone Insensitive Prostate Cancer PC-3 Cells with Autophagic Characteristics. Photodiagnosis and Photodynamic Therapy, 10, 278-287.
[10] Allison, R.R., Downie, G.H., Cuenca, R., Hu, X.H., Childs, C.J. and Sibata, C.H. (2004) Photosensitizers in Clinical PDT. Photodiagnosis and Photodynamic Therapy, 1, 27-42.
[11] Goldman, M.P., Fitzpatrick, R.E., Ross, E.V., Kilmer, S.L. and Weiss, R.A. (2013) Lasers and Energy Devices for the Skin. CRC Press Llc., Florida.
[12] Jang, Y.H., Lee, D.J., Shin, J., Kang, H.Y., Lee, E.S. and Kim, Y.C. (2013) Photodynamic Therapy with Ablative Carbon Dioxide Fractional Laser in Treatment of Actinic Keratosis. Annals of Dermatology, 25, 417-422.
[13] Kaneda, Y., Yamamoto, S. and Nakajima, T. (2005) Development of HVJ Envelope Vector and Its Application to Gene Therapy. Advances in Genetics, 53, 307-332.
[14] Mima, H., Yamamoto, S., Ito, M., Tomoshige, R., Tabata, Y., Tamai, K. and Kaneda, Y. (2006) Targeted Chemotherapy against Intraperitoneally Disseminated Colon Carcinoma Using a Cationized Gelatin-Conjugated HVJ Envelope Vector. Molecular Cancer Therapeutics, 5, 1021-1028.
[15] Kaneda, Y. (2012) Virosome: A Novel Vector to Enable Multi-Modal Strategies for Cancer Therapy. Advanced Drug Delivery Reviews, 64, 730-738.
[16] Tsurudome, M. (1999) Analyses of Paramyxovirus Glycoproteins Involved in the Induction of Cell Fusion. Uirusu, 49, 61-70.
[17] Kawaguchi, Y., Miyamoto, Y., Inoue, T. and Kaneda, Y. (2009) Efficient Eradication of Hormone-Resistant Human Prostate Cancers by Inactivated Sendai Virus Particle. International Journal of Cancer, 124, 2478-2487.
[18] Kim, J. and Okada, Y. (1982) Morphological Changes in Ehrlich Ascites Tumor Cells during the Cell Fusion Reaction with HVJ (Sendai Virus): III. Morphological Characterization of HVJ Glycoproteins Integrated into the Plasma Membrane and Their Internalization by Coated Vesicles. Experimental Cell Research, 140, 127-136.
[19] Kim, J., Santos, O.A. and Park, J.H. (2014) Selective Photosensitizer Delivery into Plasma Membrane for Effective Photodynamic Therapy. Journal of Controlled Release, 191, 98-104.
[20] Tachikawa, S., El-Zaria, M.E., Inomata, R., Sato, S. and Nakamura, H. (2014) Synthesis of Protoporphyrin-Lipids and Biological Evaluation of Micelles and Liposomes. Bioorganic & Medicinal Chemistry, 22, 4745-4751.
[21] Yamauchi, M., Honda, N., Hazama, H., Tachikawa, S., Nakamura, H., Kaneda, Y. and Awazu, K. (2014) A Novel Photodynamic Therapy for Drug-Resistant Prostate Cancer Cells using Porphyrus Envelope as a Novel Photosensitizer. Photodiagnosis and Photodynamic Therapy, 11, 48-54.
[22] Inai, M., Ymauchi, M., Honda, N., Hazama, H., Tachikawa, S., Nakamura, H., Nishida, T., Yasuda, H., Kaneda, Y. and Awazu, K. (2015) Hemagglutinating Virus of Japan Envelope (HVJ-E) Allows Targeted and Efficient Delivery of Photosensitizer for Photodynamic Therapy against Advanced Prostate Cancer. Proceedings of Optics in the Life Sciences 2015, Vancouver, 12-15 April 2015, OM2D.3.
[23] Inai, M., Honda, N., Hazama, H., Akter, S., Fuse, S., Nakamura, H., Nishikawa, T., Kaneda, Y. and Awazu, K. (2017) Photodynamic Therapy using a Cytotoxic Photosensitizer Porphyrus Envelope That Targets the Cell Membrane. Photodiagnosis and Photodynamic Therapy, 20, 238-245.
[24] Andrejevic-Blant, S., Hadjur, C.H., BalIini, J.P., Wagnieres, G., Fontolliet, C.H., Van Den Bergh, H. and Monnier, P.H. (1997) Photodynamic Therapy of Early Squamous Cell Carcinoma with Tetra(M-Hydroxyphenyl)Chlorin: Optimal Drug-Light Interval. British Journal of Cancer, 76, 1021-1028.
[25] D’Hallewin, M.A., Kochetkov, D., Viry-Babel, Y., Leroux, A., Werkmeister, E., Dumas, D., Gräfe, S., Zorin, V., Guillemin, F. and Bezdetnaya, L. (2008) Photodynamic Therapy with Intratumoral Administration of Lipid-Based mTHPC in a Model of Breast Cancer Recurrence. Lasers in Surgery and Medicine, 40, 543-549.
[26] Matsushima-Miyagi, T., Hatano, K., Nomura, M., Li-Wen, L., Nishikawa, T., Saga, K., Shimbo, T. and Kaneda, Y. (2012) TRAIL and Noxa Are Selectively Upregulated in Prostate Cancer Cells Downstream of the RIG-I/MAVS Signaling Pathway by Nonreplicating Sendai Virus Particles. Clinical Cancer Research, 18, 6271-6283.
[27] Iinuma, S., Farshi, S.S., Ortel, B. and Hasan, T. (1994) A Mechanistic Study of Cellular Photodestruction with 5-Aminolaevulinic Acid-Induced Porphyrin. British Journal of Cancer, 70, 21-28.
[28] Colasanti, A., Kisslinger, A., Quarto, M. and Riccio, P. (2004) Combined Effects of Radiotherapy and Photodynamic Therapy on an in Vivo Human Prostate Model. ActaBiochimicaPolonica, 51, 1039-1046.
[29] Lin, T.Y., Guo, W., Long, Q., Ma, A., Liu, Q., Zhang, H., Huang, Y., Chandrasekaran, S., Pan, C., Lam, K.S. and Li, Y. (2016) HSP90 Inhibitor Encapsulated Photo-Theranostic Nanoparticles for Synergistic Combination Cancer Therapy. Theranostics, 6, 1324-1335.
[30] Nakajima, T., Itai, T., Wada, H., Yamauchi, T., Kiyohara, E. and Kaneda, Y. (2013) A Novel Therapy for Melanoma and Prostate Cancer using a Non-Replicating Sendai Virus Particle (HVJ-E). In: Wei, M. and Good, D., Eds., Novel Gene Therapy Approaches, Intech, London, 157-181.
[31] Fujita, K., Nakai, Y., Kawashima, A., Ujike, T., Nagahara, A., Nakajima, T., Inoue, T., Lee, C.M., Uemura, M., Miyagawa, Y., Kaneda, Y. and Nonomura, N. (2017) Phase I/II Clinical Trial to Assess Safety and Efficacy of Intratumoral and Subcutaneous Injection of HVJ-E in Castration-Resistant Prostate Cancer Patients. Cancer Gene Therapy, 24, 277-281.
[32] Foster, T.H., Giesselman, B.R., Hu, R., Kenney, M.E. and Mitra, S. (2010) Intratumor Administration of the Photosensitizer Pc 4 Affords Photodynamic Therapy Efficacy and Selectivity at Short Drug-Light Intervals. Translational Oncology, 3, 135-141.
[33] Mannino, S., Molinari, A., Sabatino, G., Ciafrè, S.A., Colonel, M., Maira, G., Anile, C., Arancia, G. and Mangiola, A. (2008) Intratumoral vs. Systemic Administration of Meta-Tetrahydroxyphenylchlorin for Photodynamic Therapy of Malignant Gliomas: Assessment of Uptake and Spatial Distribution in C6 Rat Glioma Model. International Journal of Immunopathology and Pharmacology, 21, 227-231.
[34] Anatelli, F., Mroz, P., Liu, Q., Yang, C., Castano, A.P., Swietlik, E. and Hamblin, M.R. (2006) Macrophage-Targeted Photosensitizer Conjugate Delivered by Intratumoral Injection. Molecular Pharmaceutics, 3, 654-664.
[35] Goins, B., Phillips, W.T. and Bao, A. (2016) Strategies for Improving the Intratumoral Distribution of Liposomal Drugs in Cancer Therapy. Expert Opinion on Drug Delivery, 13, 873-889.

comments powered by Disqus

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.